Login
$COAG
$39.06 -$1.80 (4.42%) Live

$COAG SEC Filings

Filed On Filing
10 Nov 2026 10-Q
10 Nov 2026 8-K: Results of Operations and Financial Condition

Dosed first participant in Phase 1 clinical trial of HMB-003 for management of heavy menstrual bleeding,

06 Nov 2026 SCHEDULE 13G/A
25 Sep 2026 Form 4: Walbert Keli, Director

Granted 36,000 Stock Option (Right to Buy)

25 Sep 2026 Form 3: Walbert Keli, Director

No securities owned

24 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

14 Aug 2026 SCHEDULE 13G
14 Aug 2026 SCHEDULE 13G
12 Aug 2026 SCHEDULE 13G
11 Aug 2026 10-Q
11 Aug 2026 8-K: Results of Operations and Financial Condition

Multiple scientific data presentations, including five oral presentations across three programs, at the International Society on Thrombosis and Haemostasis (ISTH) 2026 Congress in Paris, France

07 Aug 2026 SCHEDULE 13G
06 Aug 2026 SCHEDULE 13G
05 Aug 2026 SCHEDULE 13G
17 Jun 2026 Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others

Bought 6,146 shares ($153K) · Bought 61,523 shares ($1.54M)

21 May 2026 Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others

Bought 3,802 shares ($94.9K) · Bought 996 shares ($24.8K)

21 May 2026 10-Q
21 May 2026 8-K: Results of Operations and Financial Condition

Completed Initial Public Offering in May 2026, raising gross proceeds of $346.7 million and listing on Nasdaq

14 May 2026 Form 4: Ra Capital MANAGEMENT, L.p., 10% owner and 3 others

Bought 6,387 shares ($159K)

14 May 2026 Form 3: Ai Den-mab Llc, 10% owner and 4 others

Holds 4,876,344 shares of Common Stock

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support